Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Scrip Asks…What Does 2023 Hold For Biopharma? Part 8: Therapeutic Area Advances
Neuroscience and oncology fuel high hopes for therapeutic R&D progress among 90-plus surveyed biopharma industry leaders.
GSK Tries To Chase Down Pfizer With Phase III Pentavalent Meningococcal Vaccine Data
Phase III data for a vaccine combining Bexsero and Menveo demonstrated non-inferiority. GSK hopes to file it for approval soon, while Pfizer’s candidate has an October FDA action date.
ViiV’s Bid To Switch HIV Patients To Cabenuva Boosted By Biktarvy Head-To-Head
A new head-to-head proves Cabenuva is a match for Gilead’s Biktarvy, which should boost uptake of the long-acting HIV treatment.
Merck & Co. And Gates Foundation Drug Hunters Hopeful Of A TB Breakthrough
The Bill & Melinda Gates Foundation has brought together big pharma companies and academic institutes in a non-profit venture to find new drugs to improve tuberculosis treatment. One participant, Merck & Co, talks to Scrip about two promising novel molecules that it discovered for the Foundation’s Medical Research Institute to develop.
GSK Ends Pact with Vir For New COVID Treatments
Its Xevudy partner GSK is pulling out but Vir is going to carry on looking for new COVID-19 solutions independently, or with other partners.
Gilead CAR-T Joins Billion-Dollar Club As Biktarvy Sales Cross $10bn Mark
Yescarta surged ahead of competitors Kymriah and Breyanzi, helping Gilead’s oncology sales exceed $2bn, while the company reported the strongest sales in its HIV-dominated core business since 2015.
GSK Exceeded Expectations In 2022, Now Looking For Edge Over Pfizer In RSV Battle
Having outperformed in 2022, GSK is gearing up for key regulatory and market access decisions on its RSV vaccine, but is confident it holds superior data compared with rival Pfizer.
Gilead Keeps Focus On HIV, Long-Acting Drugs And Growth Through Oncology
Even with top-seller Biktarvy and its preventive therapy, Descovy, protected beyond this decade from generics, Gilead is investing aggressively in long-acting HIV candidates and its oncology pipeline.
Aridis' Monoclonal Antibody Rouses Analyst Optimism Despite Pneumonia Phase III Miss
The US biotech’s lead candidate missed the mark in a Phase III hospital-related pneumonia trial due to low recruitment affected by macroeconomic headwinds but analysts retain high hopes for another upcoming study.
10 Clinical Trials To Watch Out For In 2023
Scrip surveys the Phase III clinical trial readout landscape and picks 10 of the more interesting studies set to report in 2023, with a few added extras. AstraZeneca, Novo Nordisk, Novartis and Roche feature heavily.
Vir CEO George Scangos, Set To Retire, Reflects On A Long Career In Biotech
Bayer pharmaceuticals executive Marianne De Backer will succeed Scangos at Vir, tasked with advancing several mid-stage programs in areas like hepatitis B and influenza to late-stage development.
Phase III Results Show Moderna Could Challenge In Blockbuster RSV Vaccine Market
Moderna has moved fast to catch up with GSK and Pfizer, but will still be up to a year behind in reaching the market in the burgeoning RSV market.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.